JPRN-jRCTs031200338招募中未知
Study to investigate the effects of the combined use of lurasidone and cognitive function rehabilitation (NEAR) on cognitive function in patients with schizophrenia - VICTORY-S
akagome Kazuyuki0 个研究点目标入组 170 人开始时间: 2021年2月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 60age old（—）
- 性别
- All
入选标准
- •1) Patients who meet the DSM-5 criteria for schizophrenia
- •2) Patients who have the capacity to give consent and who are able to give written consent from themselves.
- •3) Outpatients
- •4) Male and female patients aged 18-60 years on the date of informed consent
- •5) Patients who wish to switch to an antipsychotic medication and to whom their physician agrees
- •6) Patients who are not at risk of self-injury or other injury during the past 6 months from the date of informed consent
- •7) Patients without acute illness requiring treatment
- •8) For patients with chronic disease (E.G., hypertension), treatment was continued for 1 month prior to participation and the patient's condition remained stable
- •9) Patients who can participate in 2 weekly cognitive rehabilitation sessions (Each session lasts approximately 60 to 75 minutes)
- •10) Patients who can undergo neuropsychological evaluation (BAC App)
- •11) Patients with an antipsychotic chlorpromazine (CP) equivalent of 1,000 mg/day or less in the past 30 days from the date of informed consent.
- •12) Patients whose primary antipsychotic type has not changed in the last 30 days from the date of informed consent
排除标准
- •1) Patients with pre-morbid IQ less than 70 on the JART-25 test
- •2) Patients with impaired hearing or vision
- •3) Patients whose native language is not Japanese
- •4) Patients currently being treated with lurasidone, paliperidone, or clozapine
- •5) Patients taking three or more antipsychotic drugs
- •6) Patients with a history of resistance to treatment as evidenced by the fact that over the past 12 months from the date of informed consent, treatment with at least 2 appropriate doses of antipsychotics (dose indicated in the package insert) for at least 6 weeks did not improve the outcome.
- •7)Patients under treatment with psychotropic drugs known to affect cognitive function such as methamphetamine etc.
- •8)Patients who have received an antipsychotic sustained-release injection in the past 6 weeks from the date consent was obtained.
- •9)Patients with a history of electroconvulsive therapy (ECT) during the past 6 months from the date of informed consent, or patients with a history of potential need for ECT during the study.
- •10) Patients who are likely to have attempted suicide during this study.
- •11) Patients with a history of intracranial disease or CNS disease (E.G., stroke, traumatic brain injury, epilepsy, parkinsons disease,etc.).
- •12) Patients with clinically serious physical disorders
- •13) Patients with a history of alcohol, drug abuse, or dependence within the past 6 months from the date of consent.
- •14) Pregnant women or women who wish to become pregnant.
- •15) Women who are breastfeeding.
- •16) Patients who have undergone cognitive rehabilitation within 6 months prior to screening test
- •17) Patients with contraindications to latuda tablets
- •a) Comatose patient
- •b) Patients under the strong influence of central nervous system depressants such as barbiturates
- •c) Patients requiring treatment with a potent CYP3A4 inhibitor (azole antifungals (itraconazole, voriconazole, miconazole (oral agent, oral cavity agent, parenteral ingection), fluconazole, fosfluconazole, posaconazole), HIV protease inhibitors (ritonavir, lopinavir/ritonavir, nelfinavir, darunavir, atazanavir, fosamprenavir), preparations containing cobicistat, clarithromycin, etc.) or a potent CYP3A4 inducer (rifampin, phenytoin, etc.).
- •d) Patients receiving epinephrine (unless epinephrine is used for emergency treatment of anaphylaxis)
- •e) Patients with a history of hypersensitivity to ingredients of latuda tablets
- •18) Patients with contraindications to paliperidone products
- •a) comatose patient
- •b) Patients under the strong influence of central nervous system depressants such as barbiturates
- •c) Patients receiving epinephrine (unless epinephrine is used for emergency treatment of anaphylaxis)
- •d) Patients with a history of hypersensitivity to ingredients of paliperidone and risperidone.
- •e) Patients with moderate to severe renal impairment (CrCl < 50 mL/min)
- •19) Patients judged to be inappropriate as research subjects by the investigator and the sub-investigator
研究者
相似试验
已完成
不适用
A study for evaluating the effect of the combined intake of GABA, extract of Hemerocallis fulva, and extract of Apocynum venetum on sleep: randomized, placebo-controlled, double blind traial, cross-over studyHealthy adultJPRN-UMIN000023431Pharma Foods International Co., Ltd.20
招募中
不适用
Combined human milk oligosaccharides (HMOs) and probiotics intervention for children with autism.Autism spectrum disorderDysfunctional behaviourMicrobiome-gut-brain dysfunctionMental Health - Autistic spectrum disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonMental Health - Other mental health disordersACTRN12621001575820niversity of Queensland60
尚未招募
不适用
Study conducted to see the effect of swyambhuva guggulu vati and vatari taila in knee osteoarthritis.CTRI/2022/09/045250BVVS Ayurved Medical College and Hospital
尚未招募
2 期
An Ayurvedic Management Of Simple MyopiaCTRI/2023/07/055289Dr Mohana Kumari
尚未招募
3 期
Ayurvedic Management Of HypothyroidismCTRI/2024/07/070125Dr Meghna Dhapse